Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia
- PMID: 9029140
Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia
Abstract
IL-10 protects mice from LPS-induced lethality. To determine the effects of IL-10 on LPS-induced inflammatory responses, six Papio anubis baboons were i.v. injected with a sublethal dose of LPS (Salmonella typhimurium; 500 microg/kg) directly preceded by either human rIL-10 (n = 3, 500 microg/kg) or diluent (n = 3). IL-10 strongly inhibited LPS-induced release of TNF, IL-6, IL-8, and IL-12 (all p < 0.05). By contrast, IL-10 did neither influence the activation of the coagulation system (plasma levels of thrombin/antithrombin III complexes), nor the activation of the fibrinolytic system (plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor type I, and plasmin/alpha 2-antiplasmin complexes). IL-10 modestly attenuated neutrophilic leukocytosis and neutrophil degranulation (plasma concentrations of elastase/alpha1-antitrypsin complexes) (both p < 0.05). Changes in surface TNF receptor expression on circulating granulocytes were not affected by IL-10. These results suggest that during sublethal endotoxemia the predominant anti-inflammatory effect of IL-10 treatment is inhibition of proinflammatory cytokine release.
Similar articles
-
Inhibition of plasmin activity by tranexamic acid does not influence inflammatory pathways during human endotoxemia.Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):483-8. doi: 10.1161/01.ATV.0000118280.95422.48. Epub 2004 Jan 22. Arterioscler Thromb Vasc Biol. 2004. PMID: 14739127 Clinical Trial.
-
Interleukin-12 induces sustained activation of multiple host inflammatory mediator systems in chimpanzees.J Infect Dis. 1999 Mar;179(3):646-52. doi: 10.1086/314636. J Infect Dis. 1999. PMID: 9952371
-
Leukocyte, plasma, and organ-associated cytokine profiles in an animal model of acute inflammation.APMIS. 2008 May;116(5):352-60. doi: 10.1111/j.1600-0463.2008.00982.x. APMIS. 2008. PMID: 18452425
-
Staging of the pathophysiologic responses of the primate microvasculature to Escherichia coli and endotoxin: examination of the elements of the compensated response and their links to the corresponding uncompensated lethal variants.Crit Care Med. 2001 Jul;29(7 Suppl):S78-89. doi: 10.1097/00003246-200107001-00026. Crit Care Med. 2001. PMID: 11445739 Review.
-
Interleukin-10: potential benefits and possible risks in clinical infectious diseases.Clin Infect Dis. 1998 Dec;27(6):1497-507. doi: 10.1086/515032. Clin Infect Dis. 1998. PMID: 9868667 Review.
Cited by
-
Injury induces deficient interleukin-12 production, but interleukin-12 therapy after injury restores resistance to infection.Ann Surg. 2000 Feb;231(2):253-61. doi: 10.1097/00000658-200002000-00015. Ann Surg. 2000. PMID: 10674618 Free PMC article.
-
Immunity and Coagulation in COVID-19.Int J Mol Sci. 2024 Oct 19;25(20):11267. doi: 10.3390/ijms252011267. Int J Mol Sci. 2024. PMID: 39457048 Free PMC article. Review.
-
Potential Targets to Mitigate Trauma- or Sepsis-Induced Immune Suppression.Front Immunol. 2021 Feb 25;12:622601. doi: 10.3389/fimmu.2021.622601. eCollection 2021. Front Immunol. 2021. PMID: 33717127 Free PMC article.
-
Pathophysiology of pulmonary complications of acute pancreatitis.World J Gastroenterol. 2006 Nov 28;12(44):7087-96. doi: 10.3748/wjg.v12.i44.7087. World J Gastroenterol. 2006. PMID: 17131469 Free PMC article. Review.
-
Relating circulating thyroid hormone concentrations to serum interleukins-6 and -10 in association with non-thyroidal illnesses including chronic renal insufficiency.BMC Endocr Disord. 2008 Jan 22;8:1. doi: 10.1186/1472-6823-8-1. BMC Endocr Disord. 2008. PMID: 18211669 Free PMC article.